- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02288949
Stratification of the Acute Respiratory Distress Syndrome (STANDARDS)
STratification AND Outcome of Patients With the Acute Respiratory Distress Syndrome
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In 1994, the American-European Consensus Conference (AECC) defined ARDS as follows: 1) acute and sudden onset of severe respiratory distress, 2) bilateral infiltrates on frontal chest radiograph, 3) absence of left atrial hypertension or no clinical signs of left heart failure, and 4) severe hypoxemia, as PaO2/FiO2 ratio <200 mmHg, regardless of FIO2 or PEEP levels. Although this definition could be adequate for epidemiologic studies, it is not adequate for inclusion of patients into therapeutic clinical trials. In 2012, a proposal for updating the ARDS definition (the Berlin criteria) was published and an empirical classification was proposed according to three PaO2/FiO2 cut-off values at ARDS onset: severe (≤100 mmHg), moderate (>100-≤200), and mild (>200-≤300) on PEEP≥5 cmH2O. However, despite that there is sufficient evidence about the interactions between PEEP and FiO2, the Berlin criteria did not mandate the assessment of hypoxemia at 24 hours under standarized guidelines.
The PaO2/FIO2 can be easily manipulated. Alterations in PEEP and FIO2 can dramatically change the PaO2/FIO2. Despite recent reports on the effects of standardized ventilator settings on PaO2/FIO2 and fulfillment of AECC definitions of ARDS, it is still a matter of debate whether the assessment of hypoxemia at 24 hours is the most appropriate tool for stratifying lung severity in patients with ARDS.
The investigators will examine whether the assessment of hypoxemia at 24 h after ARDS diagnosis under standard guidelines for ventilatory management have an impact on the stratification of lung severity and on predicting mortality of ARDS patients in the intensive care unit.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Cuenca, Spain, 16002
- Hospital Virgen De La Luz
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients meeting the AECC definition for ARDS on PEEP greater or equal than 5 cmH2O (or the Berlin criteria for moderate and severe ARDS).
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Prospective cohort
Stratification of patients admitted into a network of Spanish ICUs.
|
Patients will be stratified based on the values of relevant demographics, pulmonary and systemic variables in relation to mortality in the intensive care unit.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
range of values of variables associated with the highest or lowest mortality
Time Frame: within the first 24 h of ARDS onset
|
within the first 24 h of ARDS onset
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
stratification by risk of death based on variables associated with worst outcome
Time Frame: ICU stay
|
ICU stay
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jesús Villar, MD, PhD, Hospital Universitario Dr. Negrin
Publications and helpful links
General Publications
- Villar J, Gonzalez-Martin JM, Ambros A, Mosteiro F, Martinez D, Fernandez L, Soler JA, Parra L, Solano R, Soro M, Del Campo R, Gonzalez-Luengo RI, Civantos B, Montiel R, Pita-Garcia L, Vidal A, Anon JM, Ferrando C, Diaz-Dominguez FJ, Mora-Ordonez JM, Fernandez MM, Fernandez C, Fernandez RL, Rodriguez-Suarez P, Steyerberg EW, Kacmarek RM; Spanish Initiative for Epidemiology, Stratification and Therapies of ARDS (SIESTA) Network. Stratification for Identification of Prognostic Categories In the Acute RESpiratory Distress Syndrome (SPIRES) Score. Crit Care Med. 2021 Oct 1;49(10):e920-e930. doi: 10.1097/CCM.0000000000005142.
- Villar J, Ambros A, Mosteiro F, Martinez D, Fernandez L, Ferrando C, Carriedo D, Soler JA, Parrilla D, Hernandez M, Andaluz-Ojeda D, Anon JM, Vidal A, Gonzalez-Higueras E, Martin-Rodriguez C, Diaz-Lamas AM, Blanco J, Belda J, Diaz-Dominguez FJ, Rico-Feijoo J, Martin-Delgado C, Romera MA, Gonzalez-Martin JM, Fernandez RL, Kacmarek RM; Spanish Initiative for Epidemiology, Stratification and Therapies of ARDS (SIESTA) Network. A Prognostic Enrichment Strategy for Selection of Patients With Acute Respiratory Distress Syndrome in Clinical Trials. Crit Care Med. 2019 Mar;47(3):377-385. doi: 10.1097/CCM.0000000000003624.
- Villar J, Martinez D, Mosteiro F, Ambros A, Anon JM, Ferrando C, Soler JA, Montiel R, Vidal A, Conesa-Cayuela LA, Blanco J, Arrojo R, Solano R, Capilla L, Del Campo R, Civantos B, Fernandez MM, Aldecoa C, Parra L, Gutierrez A, Martinez-Jimenez C, Gonzalez-Martin JM, Fernandez RL, Kacmarek RM; Stratification and Outcome of Acute Respiratory Distress Syndrome (STANDARDS) Network. Is Overall Mortality the Right Composite Endpoint in Clinical Trials of Acute Respiratory Distress Syndrome? Crit Care Med. 2018 Jun;46(6):892-899. doi: 10.1097/CCM.0000000000003022.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ACPVM-2014
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Respiratory Distress Syndrome (ARDS)
-
APR Applied Pharma Research s.a.WithdrawnSARS-CoV 2 | COVID | ARDS | Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) | Dyspnea | ALI
-
NeuroRx, Inc.RecruitingSARS-CoV 2 | COVID | ARDS | Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) | Dyspnea | ALIUnited States
-
Wolfson Medical CenterUnknown
-
Tanta UniversityRecruitingAcute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) | Respiratory Distress Syndrome, PediatricEgypt
-
Aqualung Therapeutics Corp.Not yet recruitingAcute Respiratory Distress Syndrome (ARDS)
-
Unity Health TorontoRecruitingAcute Respiratory Distress Syndrome (ARDS)Canada, Spain, Italy, Brazil
-
Hospices Civils de LyonTerminatedAcute Respiratory Distress Syndrome (ARDS)France
-
Policlinico HospitalCompletedAcute Respiratory Distress Syndrome (ARDS)Italy
-
Gamaleya Research Institute of Epidemiology and...Not yet recruitingAcute Respiratory Distress Syndrome (ARDS)
-
Hospices Civils de LyonCompletedAcute Respiratory Distress Syndrome (ARDS)France
Clinical Trials on stratification
-
University of Texas Southwestern Medical CenterActive, not recruitingColoRectal CancerUnited States
-
Chinese PLA General HospitalCompleted
-
University Health Network, TorontoRecruiting
-
Michael ArztRecruitingCoronary Artery Disease | Atrial Fibrillation | Sleep-disordered Breathing (SDB) | Elective Coronary Artery Bypass Grafting (CABG) SurgeryGermany
-
Ahram Canadian UniversityCompletedBreast Cancer | Breast Cancer FemaleEgypt
-
Charite University, Berlin, GermanyUnknown
-
Institute for Clinical Evaluative SciencesCompleted
-
Jordi Gol i Gurina FoundationCompleted
-
Jubilee Mission Medical College and Research InstituteCompleted
-
Zhang longjiang,MDRecruitingAdherence, Medication | Primary Prevention | Cardiovascular Risk Factors | StatinChina